Sign in

Alan Yu

@alanyuneph.bsky.social
786 followers 436 following 30 posts

Nephrologist, physician-scientist. Director, Division of Nephrology, Jared Grantham Kidney Institute, University of Kansas. Opinions are my own. #NephSky

PostsRepliesMedia
Alan Yu @alanyuneph.bsky.social · 29/04/2026
@kidneyboy.bsky.social is in the house!
030
Reposted by Alan Yu
ASN Publications @asnpublications.bsky.social · 02/03/2026
Bone marrow-derived inflammatory signals may shape glomerular disease in ways that we are only beginning to understand. Read this article in #ASNKidneyNews following one of the most prominent and debated candidates, suPAR: kidney.pub/KN1802-15
033
Alan Yu @alanyuneph.bsky.social · 24/12/2025
🔥Proud to share our latest #PKD prognostic model from CRISP IV In ADPKD pts with normal eGFR we can predict probability of kidney failure 15 years later with C-index >0.8 Uses only TKV + data obtained in usual clinical care
021
Reposted by Alan Yu
ASN Publications @asnpublications.bsky.social · 24/12/2025
Autosomal dominant polycystic kidney disease (ADPKD) is linked to mutations in PKD1 and PKD2 genes, affecting cation channel complexes in kidney cell cilia. This #ASNJASN study explored ways to increase these complexes in cilia to prevent kidney cyst formation: kidney.pub/JASN0942
031
Reposted by Alan Yu
ASN Publications @asnpublications.bsky.social · 09/12/2025
Cystogenesis and interstitial fibrosis are contributing factors to kidney failure in individuals with ADPKD. This #ASNJASN research examines the role of Integrin Alpha1 Beta1 in a mouse model: kidney.pub/JASN0941 #BasicResearch @rachellennon.bsky.social
054
Alan Yu @alanyuneph.bsky.social · 04/12/2025
Honored to have @juancarlosqvelez.bsky.social visiting KU Nephrology and the Jared Grantham Kidney Institute. Fantastic lecture on #hepatorenal syndrome (of course)👏 Lots of practical recommendations backed up by research conducted by Dr. Velez at @ochsnerhealth.bsky.social
050
Reposted by Alan Yu
Journal of Clinical Investigation @jci.org · 03/12/2025
~15 years ago, Dr. Fred Coe put forward the “vas washdown” model for explaining kidney stone formation @alanyuneph.bsky.social & team now report on a new mouse model, showing kidney-specific Cldn-2 KO leads to medullary nephrocalcinosis—supporting the vas washdown model: doi.org/10.1172/JCI1...
133
Alan Yu @alanyuneph.bsky.social · 03/12/2025
Now out @jclinicalinvest led by Christine_Behm with fantastic team of collaborators👇 We discover a corticomedullary gradient for Ca in kidney and show a critical role for claudin-2, with implications for kidney stone disease. @kumedcenter.bsky.social www.jci.org/articles/vie...
153
Reposted by Alan Yu
ASN Publications @asnpublications.bsky.social · 12/11/2025
Join us in congratulating this winner of the Distinguished Leader Award, an ASN Midcareer Award: Reem A. Mustafa, MD PhD MPH FASN. Read more about her work in #ASNKidneyNews: kidney.pub/KN1710-41
051
Reposted by Alan Yu
ASN Publications @asnpublications.bsky.social · 13/11/2025
New podcast alert! Dr. Priya Vart discusses the results of his study, “Effects of Dapagliflozin on Health-Related Quality of Life in Patients with CKD,” with #ASNJASN Deputy Editor Manjula Kurella Tamura: kidney.pub/JPOD0776
021
Reposted by Alan Yu
Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 08/11/2025
And in the evening - a CAR T in refractory SLE - a PKD trial - increasing PD in Vets - Povetacicept in IgA - TESTING Longterm term data - what do the AHA/ACC BP guidelines mean? #KidneyWk
LBRO
063
Reposted by Alan Yu
ASN Publications @asnpublications.bsky.social · 06/11/2025
Starting Soon! Join us for the 2025 Best of ASN Journals session at #KidneyWk. Join us Tomorrow, Thursday, November 6 at 2:00 PM in Grand Ballroom A of the George R. Brown Convention Center for a lively discussion and check out the article collection below. kidney.pub/BestOf2025
041
Reposted by Alan Yu
ASN Publications @asnpublications.bsky.social · 06/11/2025
The 2025 #ASNJASN #ASNCJASN and #ASNKidney360 Trainees of the Year are Benoit ​Brilland, Thomas Bais, and Yuhei Noda! This prize celebrates the best article submitted to each journal by a trainee as the first author. See more about the contest and this year's winners: kidney.pub/TraineeOf...
153
Reposted by Alan Yu
ASN Publications @asnpublications.bsky.social · 22/08/2025
New in #ASNJASN: an epigenetic CRISPR Screen was used for the first time to identify critical genes and pathways involved in vascular calcification. kidney.pub/JASN0793
032
Alan Yu @alanyuneph.bsky.social · 16/08/2025
Who says there are no good treatments for AKI? 👇Classic HRS-AKI with dramatic reversal by terlipressin #medsky #nephsky
Serum creatinine trajectory showing rapid rise to peak and prompt recovery over 3 days
130
Reposted by Alan Yu
American Journal of Kidney Diseases @ajkd.bsky.social · 21/07/2025
NEW on the #AJKDBlog: @maximalchange.bsky.social interviews the authors of a recent review of ADPKD, Sara S. Jdiaa and Reem A. Mustafa, and discusses prognosis, goals, and monitoring. bit.ly/Jdiaa25 (FREE)
011
Reposted by Alan Yu
ASN Publications @asnpublications.bsky.social · 20/07/2025
In a recent #ASNJASN article, authors report that ephrin-B1 at slit diaphragm suppresses cdc42 activity by preventing the interaction of Par6 with cdc42 and functions to keep the specialized phenotype of podocytes. Read more: kidney.pub/JASN0728 #BasicResearch
052
Reposted by Alan Yu
Delthia Ricks @dricks.bsky.social · 18/07/2025
Genetically modified gut bacteria show promise of combating kidney stones in clinical trial medicalxpress.com/news/2025-07...
medicalxpress.com
Genetically modified gut bacteria show promise for combating kidney stones in clinical trial
The human gut microbiome has been shown to impact health in a myriad of ways. The type and abundance of different bacteria can impact everything from the immune system to the nervous system. Now, rese...
086
Reposted by Alan Yu
American Journal of Kidney Diseases @ajkd.bsky.social · 19/07/2025
NEW on the #AJKDBlog: @maximalchange.bsky.social interviews the authors of a recent review of ADPKD, Sara S. Jdiaa and Reem A. Mustafa, and discusses prognosis, goals, and monitoring. bit.ly/Jdiaa25 (FREE)
043
Reposted by Alan Yu
ASNKidney @asnkidney.bsky.social · 14/07/2025
⏳ One week left to apply. The Fellows’ Travel Support Scholarship gives nephrology fellows $1,000 to attend the UAB CRRT Academy. Train in person, build practical CRRT skills, and learn through simulation and expert-led sessions. Apply by Monday, July 21 👉 bit.ly/3FGntEx
022
Reposted by Alan Yu
Jordy Cohen @jordybc.bsky.social · 15/07/2025
Guidelines no longer recommend holding typical first-line antihypertensive meds since renin will most often still be suppressed despite being on them in true PA. Growing evidence supports proceeding with screening Hot off the press from the Endo Society: www.endocrine.org/clinical-pra...
endocrine.org
Primary Aldosteronism
A new Endocrine Society guideline on Primary Aldosteronism updates a 2016 guideline, and suggests that everyone who is diagnosed with hypertension have their levels of aldosterone, renin, and potassiu...
2166
Reposted by Alan Yu
ASN Publications @asnpublications.bsky.social · 16/07/2025
Could gene-targeted therapy be coming for autosomal dominant polycystic kidney disease? Farabursen, a new medication acquired by Novartis offers to potentially impact cyst formation and even regression. kidney.pub/KN1707-07 #ASNKidneyNews @nephrosparks.bsky.social
094
Reposted by Alan Yu
ISNkidneycare @theisn.org · 07/07/2025
𝗡𝗘𝗪 𝗥𝗘𝗦𝗢𝗨𝗥𝗖𝗘 𝗔𝗟𝗘𝗥𝗧: Download our #ADPKD infographic for a quick overview of diagnosis, delaying progression, complications & more. A handy resource for clinicians and patients alike! ⬇️https://www.theisn.org/wp-content/uploads/2025/07/ADPKD-Infographic.pdf
134
Alan Yu @alanyuneph.bsky.social · 17/07/2025
🔥Submit a Late-Breaking Clinical Trial and have your study considered for contemporaneous publication in JASN, NEJM @nejm.org or Lancet @thelancet.com
011
Reposted by Alan Yu
ASN Publications @asnpublications.bsky.social · 06/07/2025
Understanding the role of alternative splicing in podocyte biology may lead to theraputic options for patients with glomerular hypertension. Read more in a #BasicResearch article: kidney.pub/JASN0706 #ASNJASN
031
Reposted by Alan Yu
Moe Mahjoub @mahjoublab.bsky.social · 02/07/2025
The 2026 RFAs for grant and fellowship awards from @pkdfoundation.bsky.social are out! Grant: pkdcure.org/research/gra... Fellowship: pkdcure.org/research/fel... LOIs are due August 11. Send us your best ideas!!
pkdcure.org
Grant Applications - Polycystic kidney disease | PKD treatment research | PKD Foundation
PKD Foundation Research RFA - With PKD Connect, no one will ever face polycystic kidney disease alone. Because patients, family and loved ones will always be connected to others who understand firstha...
044
Reposted by Alan Yu
ASN Publications @asnpublications.bsky.social · 02/06/2025
The June issue of JASN is now available online! Topics covered include: - Blood Transfusion during Myocardial Infarction in CKD - COL4A5 Variants in an Unselected Health System Population - and more Check out the issue: journals.lww.com/jas... #ASNJASN Cover by @ecorneclegall.bsky.social et al.
JASN June 2025
041
Reposted by Alan Yu
Alex Chang, MD @alexchangmd.bsky.social · 31/05/2025
Looks like the consolidation of NIDDK, NHLBI and NIAMS into “NI on Body Systems” proposed combined budget cut of 41%. #medsky #maha
062
Reposted by Alan Yu
ASN Publications @asnpublications.bsky.social · 16/05/2025
New Podcast: Dr. Tobias Hermle & Dominik Spitz discuss a proof-of-concept for whole-animal drug screening using podocyte-like Drosophila nephrocytes. Pilot screen using the novel podocytopathy platform identifies that zacopride restores slit diaphragms despite excess of Rac1. bit.ly/JPOD0677
A Drug-Screening Platform for Podocytopathies in Drosophila Nephrocytes
011
Reposted by Alan Yu
Nature @nature.com · 01/05/2025
A powerful technique that directly edits proteins in living cells promises to help researchers to study proteins in improved ways. go.nature.com/3GyiDJn
go.nature.com
Powerful protein editors offer new ways of probing living cells
Scientists deploy self-splicing protein subunits to insert strange new additions into target proteins.
0448
Reposted by Alan Yu
Simone Sanna-Cherchi 🧬 @genetickidneydoc.bsky.social · 28/04/2025
Coagulopathy: caused by nephrotic syndrome and worsening nephrotic syndrome! Implications for future studies aiming at risk stratification for pro-thrombotic predisposition and treatment #FSGS #sFSGS #nephroticsyndrome
021
Reposted by Alan Yu
ASN Publications @asnpublications.bsky.social · 27/04/2025
Study shows plasma prothrombin levels modulated in vivo podocyte health and function in a rat model of glomerular disease. bit.ly/JASN0676 #ASNJASN #BasicResearch @drklotter.bsky.social
031
Reposted by Alan Yu
EMBO Molecular Medicine @embomolmed.org · 22/04/2025
📣 Don’t miss the review by @bolettalab.bsky.social & S. Clerici on metabolic and mitochondrial alterations in #PolycysticKidneyDisease and other renal #ciliopathies ➡️ doi.org/10.1038/s443... at IRCCS San Raffaele Scientific Institute
043
Reposted by Alan Yu
Fiona Loud @fionacloud.bsky.social · 22/04/2025
Kidney disease is a worldwide killer. Treat it that way www.nature.com/articles/d41...
nature.com
Kidney disease is a worldwide killer. Treat it that way
The international community has a golden opportunity to start reining in the escalating, mostly ignored global burden of chronic kidney disease.
031
Reposted by Alan Yu
PKD Foundation @pkdfoundation.bsky.social · 10/04/2025
Vanessa Westerfield and Savanna Moore presenting their poster titled, "Patient-Centered Insights on Treatment Adherence and Social Determinants of Health in Patients with Autosomal Dominant Polycystic Kidney Disease," at @nkf-professionals.bsky.social SCM. Stop by G-498 to learn more!
032
Reposted by Alan Yu
PKD Foundation @pkdfoundation.bsky.social · 10/04/2025
Check out these posters from Columbia University and University of Kansas Medical Center & Polycystic Kidney Disease Outcomes Consortium (PKDOC) in the Hereditary Kidney Disease/PKD poster aisle at @nkf-professionals.bsky.social SCM25.
021
Reposted by Alan Yu
ASN Publications @asnpublications.bsky.social · 09/04/2025
The ASN Journal Portfolio seeks early career scientists and junior faculty members interested in participating in the editorial process of peer reviewed journals to join our Junior Associate Editor (JAE) Program. Learn more and apply by May 2. bit.ly/TraineePrograms @rajmehrotra.bsky.social
032
Reposted by Alan Yu
Simone Sanna-Cherchi 🧬 @genetickidneydoc.bsky.social · 01/04/2025
This is a great opportunity for advanced trainees/junior faculties to get hands-on experience as Editors in the top nephrology portfolio! Join us and have fun with us trying to constructively push authors to publish their best science! #Nephsky #Skyneph @asnkidney.bsky.social @aspnr.bsky.social
031
Reposted by Alan Yu
Chrystal Starbird @drstarbird.bsky.social · 27/03/2025
Just want to say again I’m grateful for the people doing their best to hold it down at the NIH despite the chaos and uncertainty. I see you 🙌🏾
428248
Reposted by Alan Yu
Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 23/03/2025
Also note two large RCTs ongoing - or about to start - in France: bsky.app/profile/dgue...
0175
Reposted by Alan Yu
Alex Chang, MD @alexchangmd.bsky.social · 15/03/2025
Great study suggesting exercise slows eGFR decline: Generation 100 Study, 5-yr open-label, randomized clinical trial in Norway. journals.lww.com/jasn/fulltex... Compared with controls, RR 0.93 (95% CI: 0.75, 1.16) for the moderate-intensity and 0.75 (95% CI: 0.59, 0.95) for high-intensity groups
2103
Reposted by Alan Yu
ASN Publications @asnpublications.bsky.social · 15/03/2025
The ASN Journal Portfolio seeks early career scientists and junior faculty members interested in participating in the editorial process of peer reviewed journals to join our Junior Associate Editor (JAE) Program. Learn more and apply by May 2. bit.ly/TraineePrograms @rajmehrotra.bsky.social
054
Reposted by Alan Yu
ASN Publications @asnpublications.bsky.social · 11/03/2025
Piezo1 plays a key mechanosensory role in podocyte injury during DKD progression by mediating calcium influx and activating the NFATc1/TRPC6 signaling pathway. bit.ly/JASN0634 #ASNJASN #BasicResearch
053
Reposted by Alan Yu
༺DailyHemo༻ @dailyhemo.bsky.social · 05/03/2025
His exceptional scientific work, evidenced by many hundreds of papers and about 50 books as editor or co-editor, has left an unparalleled legacy that will inspire and serve as a guide for future generations of nephrologists. academic.oup.com/ndt/article/... #MedSky #NephSky #RenalSky
academic.oup.com
Celebrating the life and scientific contributions of Barry Brenner in nephrology
I have a vivid memory of Barry telling me in his special captain's-like home in Nantucket: ‘a simple hypothesis in medicine means nothing unless it can be
052
Reposted by Alan Yu
Stand Up for Science! @standupforscience.net · 20/02/2025
☀️📣 Looking for a STATE LEAD and VOLUNTEERS to help us #standupforscience2025 in Kansas! Know someone interested? Fill out this form: airtable.com/app4h5wUssMG... #scienceforall #sciencenotsilence
Photo of kansas with text, looking for kansas volunteers
01312
Alan Yu @alanyuneph.bsky.social · 07/02/2025
University of Kansas Nephrology and the Jared Grantham Kidney Institute are ready for Super Bowl LIX🏈 Go Chiefs🔥🔥🔥
300
Reposted by Alan Yu
National Kidney Foundation @kidney.org · 28/01/2025
BREAKING NEWS: The FDA has approved Ozempic for patients with chronic kidney disease. This means the popular injection can be used to reduce the risk of kidney disease worsening, kidney failure and death from cardiovascular disease in patients with chronic kidney disease and diabetes.
cnbc.com
FDA approves Novo Nordisk's Ozempic to treat chronic kidney disease in those with diabetes, expanding its use
Expanded Ozempic approval in the U.S. could transform how doctors treat patients with chronic kidney disease, which involves a gradual loss of kidney function.
12216
Alan Yu @alanyuneph.bsky.social · 29/01/2025
This is really cool: 👉Individualized antisense oligo treatments for patients with nano-rare mutations (i.e., <30 patients worldwide) 👉Drugs are provided for free, for life, for conditions where commercialization is unrealistic Wow!
060
Reposted by Alan Yu
Simone Sanna-Cherchi 🧬 @genetickidneydoc.bsky.social · 22/01/2025
One year at JASN! While we try to bring excellence to our beloved Journal, some people have left - @alessiafornoni.bsky.social - and some joined: welcome to new Deputy Editor Alan S.L. Yu @alanyuneph.bsky.social ! #Nephsky #Skyneph #Medsky @asnkidney.bsky.social
2101
Reposted by Alan Yu
ISNkidneycare @theisn.org · 23/12/2024
Join us in congratulating Professor Marie Trudel, winner of the ISN 2025 Lillian Jean Kaplan Prize, who will present "Bridging the Gap: PKD Research and Clinical Care Perspective" during the Kaplan PKD Session at WCN'25 ➡️ ow.ly/bfTR50UoFnx @pkdfoundation.bsky.social #NephSky
0105